Latest News, Press Releases & Events

Spyryx Biosciences Appoints Alistair Wheeler, MD MFPM as Chief Medical Officer, SPX-101 Advancing in Phase 1 as Novel Therapy for Cystic Fibrosis

Spyryx Biosciences Expands Executive Team, Appoints Pulmonary Industry Leader, Alistair Wheeler, MD, MFPM as Chief Medical Officer Recognized Expert in Respiratory Product Development SPX-101 Advancing in Phase 1 as Novel Therapy for Cystic Fibrosis Durham, NC; August 18, 2016 – Spyryx Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for respiratory diseases, including cystic […]

Continue Reading

Spyryx Biosciences Emerging Company Profile in BioCentury

EMERGING COMPANY PROFILE GOING SPLUNCING BY EMILY CUKIER-MEISNER, SENIOR WRITER Spyryx Biosciences Inc. is developing inhaled peptides for cystic fibrosis that inhibit the sodium channel responsible for regulating fluid volume in the lungs. The peptides could offer a pan-genotypic treatment that is more efficacious than therapies targeting CFTR. CF is caused by defects in the […]

Continue Reading

Spyryx Biosciences Announces CFFT Development Award

Spyryx Biosciences Receives Development Award from Cystic Fibrosis Foundation Therapeutics to Advance Novel Therapy for CF Durham, NC; June 25, 2015 – Spyryx Biosciences, Inc., a privately-held biopharmaceutical company developing novel therapeutics for obstructive lung diseases, announced today it has received an award from Cystic Fibrosis Foundation Therapeutics, which will support development of Spyryx’ therapeutic […]

Continue Reading